Exploring Precision Medicine and PGx: Sara Rogers, PharmD, Previews Precision Medicine World Conference 2025

Pharmacy Times^® interviewed Sara Rogers, PharmD, president of American Society of Pharmacovigilance and clinical assistant professor at Texas A&M University, on key sessions and discussions to watch at the Precision Medicine World Conference (PMWC) 2025.

Pharmacy Times: Why do you attend the Precision Medicine World Conference, and what do you see as the value of the meeting for your work?

Sara Rogers, PharmD, is the president of American Society of Pharmacovigilance and a clinical assistant professor at Texas A&M University.

Sara Rogers, PharmD: I attend the PMWC because it brings together leaders across academia, industry, and health care to discuss the latest advancements in precision medicine. For my work in pharmacogenomics (PGx), it is essential to stay informed on emerging technologies, regulatory developments, and implementation strategies that can improve patient outcomes.

Pharmacy Times: For pharmacy professionals who are interested in learning more about PGx and related practices, how might attending PMWC be beneficial?

Rogers: PMWC offers pharmacy professionals a deep dive into cutting-edge topics in PGx and precision medicine. Attendees gain exposure to the latest research, regulatory perspectives, and clinical implementation models. Sessions on PGx myths, insurance challenges, and real-world applications provide actionable insights that pharmacists can apply in patient care. Additionally, PMWC presents opportunities to engage with thought leaders across medicine and industry, making it an excellent venue for networking and collaboration.

Pharmacy Times: Have you attended past PMWC meetings, and what have been some highlights or critical questions that have arisen?

Attendees listen to a conference presentation. Image Credit: © Gennady Danilkin - stock.adobe.com

Rogers: I have attended PMWC in the past, and it continues to be one of the most impactful conferences for those working in precision medicine. One of the critical discussions that has emerged over the years is how to ensure equitable access to PGx and precision medicine. Coverage and reimbursement remain significant hurdles, and discussions at PMWC have highlighted innovative models for integrating PGx into clinical workflows. Another key theme has been the role of AI in improving PGx implementation and how real-world evidence can support broader adoption.

Pharmacy Times: Are there any speakers or sessions you think may be particularly insightful or valuable for pharmacy professionals at this meeting?

Rogers: There are several sessions at PMWC 2025 that I think pharmacy professionals should pay particular attention to:

• “PGx is Expensive and Insurance Coverage is Limited" on day 3 from 9:30 AM – 10:30 AM PT – Pharmacy professionals involved in precision medicine benefit from understanding the financial and reimbursement challenges surrounding PGx testing. This session will provide insights into payer perspectives and strategies for improving coverage.
• "Science Backing PGx is Limited" on day 3 from 11:00 AM – 12:00 PM PT – This panel will address the perception that PGx lacks sufficient evidence, despite growing clinical data supporting its utility. This discussion will be important for pharmacy professionals advocating for PGx in clinical settings.
• "What Will It Take to Make PGx the Standard of Care?" on day 3 from 2:15 PM – 3:00 PM PT – This session will tackle the barriers to broader PGx implementation, including policy, provider education, and clinical integration.

With the increasing role of AI in precision medicine, pharmacy professionals may also find sessions on AI-driven drug development, clinical metagenomics, and multi-omics approaches particularly insightful.

Pharmacy Times: What are your hopes for PMWC 2025?

Rogers: I hope PMWC 2025 will advance conversations around overcoming implementation barriers for PGx and precision medicine. Addressing myths, clarifying evidence gaps, and improving reimbursement pathways are crucial steps toward making PGx standard practice. I also look forward to networking with colleagues who are working to bridge the gap between emerging research and real-world clinical application. Ultimately, I hope this conference inspires actionable collaborations that will drive equitable access to precision medicine for all patients.